Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $20.89

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned an average recommendation of “Buy” from the ten ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $20.89.

A number of equities analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Wedbush reiterated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 target price for the company.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $8.28 on Monday. The company has a 50 day moving average price of $12.48 and a 200-day moving average price of $12.59. Y-mAbs Therapeutics has a 1-year low of $6.10 and a 1-year high of $20.90. The firm has a market cap of $370.85 million, a price-to-earnings ratio of -15.33 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. During the same period in the previous year, the firm posted ($0.18) EPS. On average, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of YMAB. Principal Financial Group Inc. purchased a new stake in Y-mAbs Therapeutics during the 3rd quarter valued at about $267,000. Barclays PLC grew its position in shares of Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after purchasing an additional 56,244 shares in the last quarter. Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $210,000. Geode Capital Management LLC lifted its position in Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after buying an additional 47,846 shares in the last quarter. Finally, State Street Corp boosted its stake in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.